Century Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Century Therapeutics, Inc. (IPSC) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$2.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-12
- Century Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $1.16M, a 63.79% increase year-over-year.
- Century Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$3.96M.
- Century Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $1.08M, a 62.87% decline year-over-year.
- Century Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $443.00K, a 80.34% decline year-over-year.
- Century Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$4.32M, a 369.35% decline from fiscal 2024.
- Century Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $1.60M.
- Century Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was -$730.00K, a 118.45% decline from fiscal 2022.
- Century Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $3.96M, a 165.57% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$2.80M 10-Q · filed 2026-08-12 | -$1.72M derived: sum of 3 quarters · filed 2026-08-12 | -$1.28M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$3.96M 10-Q · filed 2026-05-13 | -$2.88M derived: sum of 2 quarters · filed 2026-05-13 | -$2.43M derived: sum of 3 quarters · filed 2026-05-13 | -$1.73M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.52M derived: sum of 2 quarters · filed 2026-03-12 | $2.23M derived: sum of 3 quarters · filed 2026-08-12 | -$4.32M 10-K · filed 2026-03-12 |
| 2025-09-30 | $443.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.15M derived: sum of 2 quarters · filed 2026-08-12 | -$5.39M 10-Q · filed 2025-11-13 | -$2.49M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $707.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$5.84M 10-Q · filed 2026-08-12 | -$2.93M derived: sum of 3 quarters · filed 2026-08-12 | -$678.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$6.54M 10-Q · filed 2026-05-13 | -$3.64M derived: sum of 2 quarters · filed 2026-05-13 | -$1.39M derived: sum of 3 quarters · filed 2026-05-13 | -$1.62M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $2.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $5.16M derived: sum of 2 quarters · filed 2026-03-12 | $4.92M derived: sum of 3 quarters · filed 2026-03-12 | $1.60M 10-K · filed 2026-03-12 |
| 2024-09-30 | $2.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.02M derived: sum of 2 quarters · filed 2025-11-13 | -$1.30M 10-Q · filed 2025-11-13 | -$3.69M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$238.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$3.56M 10-Q · filed 2025-08-14 | -$5.94M derived: sum of 3 quarters · filed 2025-08-14 | -$3.01M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$3.32M 10-Q · filed 2025-05-15 | -$5.71M derived: sum of 2 quarters · filed 2025-05-15 | -$2.77M derived: sum of 3 quarters · filed 2025-05-15 | -$843.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$2.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $547.00K derived: sum of 2 quarters · filed 2025-03-19 | $2.48M derived: sum of 3 quarters · filed 2025-03-19 | -$730.00K 10-K · filed 2025-03-19 |
| 2023-09-30 | $2.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $4.86M derived: sum of 2 quarters · filed 2024-11-05 | $1.66M 10-Q · filed 2024-11-05 | $2.79M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $1.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$1.28M 10-Q · filed 2024-08-08 | -$145.00K derived: sum of 3 quarters · filed 2024-08-08 | $1.58M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$3.21M 10-Q · filed 2024-05-09 | -$2.07M derived: sum of 2 quarters · filed 2024-05-09 | -$348.00K derived: sum of 3 quarters · filed 2024-05-09 | $1.92M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $2.86M derived: sum of 2 quarters · filed 2024-03-14 | $5.13M derived: sum of 3 quarters · filed 2024-03-14 | $3.96M 10-K · filed 2024-03-14 |
| 2022-09-30 | $1.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $4.00M derived: sum of 2 quarters · filed 2023-11-09 | $2.83M 10-Q · filed 2023-11-09 | $1.64M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $2.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $1.10M 10-Q · filed 2023-08-09 | -$89.00K derived: sum of 3 quarters · filed 2023-08-09 | $294.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$1.17M 10-Q · filed 2023-05-11 | -$2.36M derived: sum of 2 quarters · filed 2023-05-11 | -$1.98M derived: sum of 3 quarters · filed 2023-05-11 | $631.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$805.00K derived: sum of 2 quarters · filed 2023-03-16 | $1.80M derived: sum of 3 quarters · filed 2023-03-16 | $1.49M 10-K · filed 2023-03-16 |
| 2021-09-30 | $383.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $2.99M derived: sum of 2 quarters · filed 2022-11-10 | $2.68M 10-Q · filed 2022-11-10 | $4.26M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $2.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $2.29M 10-Q · filed 2022-08-11 | $3.88M derived: sum of 3 quarters · filed 2022-08-11 | $5.76M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$311.00K 10-Q · filed 2022-05-16 | $1.27M derived: sum of 2 quarters · filed 2022-05-16 | $3.15M derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | $1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $3.47M derived: sum of 2 quarters · filed 2022-03-17 | $2.33M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $1.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $748.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | -$1.13M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |